RT Journal Article
SR Electronic
T1 Improved morpho-syntax in discourse following intensive voice treatment in Parkinson’s disease: Secondary outcome variables from a Randomized Controlled Trial (RCT)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.07.21263659
DO 10.1101/2021.10.07.21263659
A1 Amy E. Ramage
A1 Kathryn J. Greenslade
A1 Kaila Cote
A1 Jessica N. Lee
A1 Cynthia M. Fox
A1 Angela Halpern
A1 Lorraine O. Ramig
YR 2021
UL http://medrxiv.org/content/early/2021/10/11/2021.10.07.21263659.abstract
AB It is well established that voice is disordered in nearly 90% of individuals with Parkinson’s disease (PD). Given the role of voice in language expression, we pose that optimizing vocal function may lead to improved language production. Verb production is an area of language deficit in PD, particularly for verbs associated with an individual’s location of impairment (upper vs. lower limbs). It is thought that damage to the motor system, given its connection to action verbs, underlies this lexical effect. If this is the case, then treatment improving vocal motor function may also improve access to verbs. Nineteen participants with PD underwent Lee Silverman Voice Treatment (LSVT LOUD®), a 4-week intensive voice treatment (TXPD), in an IRB-approved randomized controlled voice treatment trial. Language production was contrasted with 20 untreated PD (UNTXPD) and 20 age-matched neurotypical control participants. Each provided 1-minute picture description narratives at baseline and after 4-weeks. Pre-post treatment within- and between-group comparisons identified effects of assessment time point and isolated treatment effects in the TXPD relative to UNTXPD and Controls. Given the intervention, the TXPD group demonstrated a significant increase in loudness during the picture description, as well as increased utterance length, diversity of word types used, verbs per utterance, and lexical density.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT00123084Funding StatementThe LSVT LOUD treatment trial was funded by grant R01DC0115 from the National Institute on Deafness and Other Communication Disorders (Principal Investigator: Ramig).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:data were collected at the National Center for Voice and Speech-Denver, an affiliate of the University of Colorado-Boulder (UCB). Additional screening/inclusion and demographic data were collected from neurology and otolaryngology offices in Denver, and the radiology department of the University of Colorado Health Sciences Center-Denver (UCHSC). Study procedures were approved by the institutional review board at the University of Colorado at Boulder and are shared at ClinicalTrials.gov identifier: NCT00123084. All participants provided informed written consent for participation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are held by the authors and may be available upon request.